Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions, capturing the landscape of five expanding therapeutic areas: weight loss, osteoarthritis, Alzheimer’s disease, COPD, and psychedelics.
There is no cure for having to remember countless logins/passwords.
A look at the performance of the top 15 companies across seven business-key metrics, including the latest standouts in market capitalization and creating shareholder value.
How pharma companies can reduce the risk of failure with AI-based innovations.
Could the sector please get a little ‘rate’ relief?
Nevertheless, it’s time to reassess how to leverage for greatest impact.
Closing the gender gap in pharma—and how we get there together.
Click the title above for a link to open the Pharmaceutical Executive November 2023 issue in an interactive PDF format.
